BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19903105)

  • 1. Impact of culture medium on the expansion of T cells for immunotherapy.
    Sato K; Kondo M; Sakuta K; Hosoi A; Noji S; Sugiura M; Yoshida Y; Kakimi K
    Cytotherapy; 2009; 11(7):936-46. PubMed ID: 19903105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
    Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
    Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
    Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
    Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cell culture media on the expansion efficiency and T-cell receptor Vbeta (TRBV) repertoire of in vitro expanded T cells using feeder cells.
    Block A; Rohde M; Erben U; Hammer M; Hummel M; Blunert K; Schultheiss HP; Volk HD; Noutsias M
    Med Sci Monit; 2008 May; 14(5):BR88-95. PubMed ID: 18443543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo expansion of natural killer cells for clinical applications.
    Klingemann HG; Martinson J
    Cytotherapy; 2004; 6(1):15-22. PubMed ID: 14985163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
    Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
    Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity of ex vivo-expanded T cells is correlated with expansion and CD4/CD8 ratio.
    Mercier-Letondal P; Montcuquet N; Sauce D; Certoux JM; Jeanningros S; Ferrand C; Bonyhadi M; Tiberghien P; Robinet E
    Cytotherapy; 2008; 10(3):275-88. PubMed ID: 18418773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
    Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
    Li Q; Furman SA; Bradford CR; Chang AE
    Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetanus toxoid provides efficient T-cell help for the induction of HA-1(H) cytotoxic T cells.
    Eiz-Vesper B; Horn PA; Daubert C; Khattab B; Blasczyk R
    Transfusion; 2006 Jul; 46(7):1210-20. PubMed ID: 16836569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possibility of adoptive immunotherapy with peripheral blood-derived CD3⁻CD56+ and CD3+CD56+ cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity.
    Doskali M; Tanaka Y; Ohira M; Ishiyama K; Tashiro H; Chayama K; Ohdan H
    J Immunother; 2011 Mar; 34(2):129-38. PubMed ID: 21304407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Selection of culture media for the mass production of gamma delta T cells used in adoptive immunotherapy].
    Zhou JH; Kang N; Cui LX; He W
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Dec; 33(6):644-8. PubMed ID: 22509548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.